{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:18:47Z","timestamp":1792606727332,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1124\/jpet.110.170274","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T23:40:19Z","timestamp":1278978019000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases"],"prefix":"10.1016","volume":"335","author":[{"given":"Yasunobu","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsukimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Arikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Hirase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kajino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Inatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.170274_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","article-title":"Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases","volume":"108","author":"Andersson","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"Suppl 5","key":"10.1124\/jpet.110.170274_bib2","first-page":"125","article-title":"Nocturnal acid breakthrough: clinical significance and management","volume":"21","author":"Ang","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1124\/jpet.110.170274_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for management of gastro-esophageal reflux disease","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion"},{"key":"10.1124\/jpet.110.170274_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00042737-199911000-00016","article-title":"Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion","volume":"11","author":"Dammann","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.110.170274_bib5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"10.1124\/jpet.110.170274_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0021-9258(18)84756-1","article-title":"The colorimetric determination of phosphorus","volume":"66","author":"Fiske","year":"1925","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.170274_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2036.2003.01405.x","article-title":"Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole","volume":"17","author":"Frazzoni","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","article-title":"Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies","volume":"20","author":"Furuta","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/jpet.110.170274_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bcp.2006.09.020","article-title":"Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase","volume":"73","author":"Gedda","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.110.170274_bib11","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.3748\/wjg.v11.i34.5259","article-title":"Role of potassium in acid secretion","volume":"11","author":"Geibel","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.110.170274_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","article-title":"Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole","volume":"162","author":"Graham","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.110.170274_bib13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/00365520701405579","article-title":"Systemic expression profiling of the gastric H+\/K+ ATPase in human tissue","volume":"42","author":"Herrmann","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/jpet.110.170274_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.159.7.649","article-title":"Importance of pH control in the management of GERD","volume":"159","author":"Hunt","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.110.170274_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/jpet.107.121350","article-title":"Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526)","volume":"323","author":"Ito","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.170274_bib16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","article-title":"A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis","volume":"5","author":"Kahrilas","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.110.170274_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","article-title":"Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole","volume":"14","author":"Katz","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.2006.02944.x","article-title":"Review article: acid-related disease - what are the unmet clinical needs?","volume":"23","author":"Katz","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2036.2003.01695.x","article-title":"Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia","volume":"18","author":"Malfertheiner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib20","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/S0021-9258(19)34079-7","article-title":"Interaction of a K+-competitive inhibitor, a substituted imidazo[1,2a]pyridine, with the phospho- and dephosphoenzyme forms of H+,K+-ATPase","volume":"265","author":"Mendlein","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.170274_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3565(25)23774-0","article-title":"Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749","volume":"248","author":"Nagaya","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.170274_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0022-3565(25)20193-8","article-title":"Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells","volume":"252","author":"Nagaya","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.170274_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0021-5198(19)39913-5","article-title":"Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs","volume":"55","author":"Nagaya","year":"1991","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.110.170274_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.14.4.411","article-title":"Novel approaches to the pharmacological blockade of gastric acid secretion","volume":"14","author":"Parsons","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.110.170274_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/0006-2952(95)02020-9","article-title":"Properties of the reversible, K+-competitive inhibitor of the gastric (H+\/K+)-ATPase, SK&F 97574: I. In vitro activity","volume":"50","author":"Pope","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.110.170274_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1368-5031.2005.00517.x","article-title":"Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases","volume":"59","author":"Robinson","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1124\/jpet.110.170274_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pa.28.040188.001413","article-title":"Gastric H, K-ATPase as therapeutic target","volume":"28","author":"Sachs","year":"1988","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.110.170274_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pa.35.040195.001425","article-title":"The pharmacology of the gastric acid pump: the H+,K+-ATPase","volume":"35","author":"Sachs","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.110.170274_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-3565(25)23775-2","article-title":"Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats","volume":"248","author":"Satoh","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.170274_bib30","doi-asserted-by":"crossref","first-page":"S651","DOI":"10.1016\/S0016-5085(10)63000-4","article-title":"Mechanism of inhibition of the gastric H+,K+-ATPase by a novel K+-competitive acid blocker TAK-438","volume":"138","author":"Shin","year":"2010","journal-title":"Gastroenterol"},{"key":"10.1124\/jpet.110.170274_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/jpet.107.120428","article-title":"Soraprazan: setting new standards in inhibition of gastric acid secretion","volume":"321","author":"Simon","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.170274_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1254\/jjp.82.21","article-title":"Studies on the mechanism of action of the gastric H+,K+-ATPase inhibitor SPI-447","volume":"82","author":"Tsukimi","year":"2000","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.110.170274_bib33","first-page":"S29","article-title":"Shortcomings of the first-generation proton pump inhibitors","volume":"13","author":"Tytgat","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.110.170274_bib34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2004.01957.x","article-title":"Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease","volume":"19","author":"Vakil","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.110.170274_bib35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0021-9258(18)61620-5","article-title":"Inhibition of gastric H+,K+-ATPase and acid secretion by SCH28080, a substituted pyridyl(1,2a)imidazole","volume":"262","author":"Wallmark","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.170274_bib36","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","article-title":"Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume":"118","author":"Wolfe","year":"2000","journal-title":"Gastroenterol"},{"key":"10.1124\/jpet.110.170274_bib37","first-page":"233","article-title":"Current status of acid pump antagonists (reversible PPIs)","volume":"69","author":"Wurst","year":"1996","journal-title":"Yale J Biol Med"},{"key":"10.1124\/jpet.110.170274_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270003261321","article-title":"Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers","volume":"44","author":"Yu","year":"2004","journal-title":"J Clin Pharmacol"}],"updated-by":[{"DOI":"10.1124\/jpet.115.170120err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000}}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524277764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524277764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.170274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:12:55Z","timestamp":1739977975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524277764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0022356524277764"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.170274","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.170274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}